CRISPR Therapeutics (NasdaqGM:CRSP) reports material progress in commercializing Casgevy, the first FDA approved gene editing ...

ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial ...

A sales partner offered a ray of hope that this company couldn't for itself.

Sales of Casgevy, a gene-edited treatment developed with CRISPR Therapeutics, more than tripled compared to the third quarter ...

Following over a year of slow uptake, Vertex Pharmaceuticals and CRISPR Therapeutics expect Casgevy revenues to nearly triple ...

Evercore ISI raised the firm’s price target on Crispr Therapeutics (CRSP) to $74 from $62 and keeps an Outperform rating on the shares. The updated target reflects strong momentum as Vertex ...

Oceanic ecosystems are increasingly threatened by global warming, which causes coral bleaching, species migration and, ...

Dr. Rebecca Ahrens-Nicklas and Dr. Kiran Musunru crafted a bespoke treatment that has successfully corrected the genetic ...

The earnings results for CRISPR Therapeutics (NASDAQ: CRSP) for Q4 were made public on Thursday, February 12, 2026 at 04:00 PM. Here's a comprehensive overview of the announcement. CRISPR Therapeutics ...

Muscles make up nearly 40% of the human body and power every move we make, from a child's first steps to recovery after ...

CRISPR Therapeutics (NASDAQ:CRSP) is one of the stocks that should double by 2030. On January 30, Citizens maintained an ...

Scientists are testing an entirely new way to fight heart disease: whether gene editing might offer a one-time fix for high ...